<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1715">
  <stage>Registered</stage>
  <submitdate>15/10/2007</submitdate>
  <approvaldate>15/10/2007</approvaldate>
  <nctid>NCT00545701</nctid>
  <trial_identification>
    <studytitle>Immunogenicity and Safety of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Adults</studytitle>
    <scientifictitle />
    <utrn />
    <trialacronym />
    <secondaryid>GPA11</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Influenza</healthcondition>
    <healthcondition>Orthomyxoviridae Infections</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - A/H5N1 inactivated, split-virion influenza virus

Experimental: 1 - 


Other interventions: A/H5N1 inactivated, split-virion influenza virus
0.5 mL, Intramuscular

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To provide information concerning the immunogenicity of A/H5N1 inactivated, split-virion influenza virus vaccine</outcome>
      <timepoint>Day 42 post-vaccination 1</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Aged 18 to 60 years on day of inclusion.

          -  Informed Consent Form signed.

          -  Able to attend all scheduled visits and to comply with all trial procedures.

          -  For a woman, inability to bear a child or negative urine pregnancy test.

          -  For a woman of child-bearing potential, use of an effective method of contraception or
             abstinence for at least 4 weeks prior to and at least 4 weeks after each vaccination.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Systemic hypersensitivity to any component of the vaccine or a life-threatening
             reaction after previous administration of a vaccine containing the same substances
             (egg proteins, chick proteins, thimerosal, aluminum, neomycin, formaldehyde, and
             octoxinol 9).

          -  Febrile illness (oral temperature &gt;= 37.5Â°C) on the day of inclusion.

          -  Breast-feeding.

          -  Previous vaccination with an avian flu vaccine.

          -  Participation in a clinical trial (drug, device, or medical procedure) within 4 weeks
             prior to the first vaccination.

          -  Planned participation in another clinical trial during the present trial period.

          -  Congenital or acquired immunodeficiency, or receipt of immunosuppressive therapy such
             as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or
             long-term systemic corticosteroid therapy.

          -  Chronic illness that could interfere with trial conduct or completion (e.g. cardiac,
             renal, diabetes, or auto-immune disorders).

          -  Current alcohol or drug abuse that may interfere with the subject's ability to comply
             with trial procedures.

          -  Receipt of blood or blood-derived products in the past 3 months, that might interfere
             with the assessment of immune response.

          -  Receipt of any vaccine in the 4 weeks preceding the first trial vaccination.

          -  Planned receipt of any vaccine in the 4 weeks following any trial vaccination.

          -  Thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination.

          -  Subject deprived of freedom by an administrative or court order, or in an emergency
             setting, or hospitalized without his/her consent.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>100</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Adelaide</hospital>
    <hospital> - Queensland</hospital>
    <postcode> - Adelaide</postcode>
    <postcode> - Queensland</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Sanofi Pasteur, a Sanofi Company</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The trial is a Phase II, open-label trial in healthy subjects aged 18 to 60 years to support
      the immunogenicity data from previous clinical studies.

      Objectives:

        -  To describe the immune response 21 days after each vaccination.

        -  To describe the safety profiles following each vaccination.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00545701</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Monitor</name>
      <address>Sanofi Pasteur Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>